Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.09USD
21 Feb 2018
Change (% chg)

$0.03 (+1.46%)
Prev Close
$2.06
Open
$2.05
Day's High
$2.12
Day's Low
$2.04
Volume
21,580
Avg. Vol
30,906
52-wk High
$2.95
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $62.03
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Sophiris Bio Announces Complete Enrollment In Phase 2B Topsalysin Study

* SOPHIRIS BIO ANNOUNCES COMPLETE ENROLLMENT IN PHASE 2B TOPSALYSIN STUDY OF LOCALIZED PROSTATE CANCER Source text for Eikon: Further company coverage:

Dec 11 2017

BRIEF-Sophiris Bio posts Q3 loss per share $0.09

* Sophiris Bio reports third quarter financial results and key corporate highlights

Nov 09 2017

BRIEF-bluebird bio reports qtrly ‍loss per share $1.73​

* bluebird bio reports third quarter 2017 financial results and recent operational progress

Nov 01 2017

BRIEF-SOPHIRIS BIO PROVIDES ENROLLMENT UPDATE ON TOPSALYSIN PHASE 2B STUDY

* SOPHIRIS BIO PROVIDES ENROLLMENT UPDATE ON TOPSALYSIN PHASE 2B STUDY IN LOCALIZED PROSTATE CANCER

Oct 02 2017

BRIEF-SOPHIRIS BIO ENTERED INTO LOAN AND SECURITY AGREEMENT OF UP TO $10 MLN IN TWO TERM LOANS​

* SOPHIRIS BIO- ‍ANNOUNCED THAT IT ENTERED INTO A LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK AND MAY BORROW UP TO $10 MILLION IN TWO TERM LOANS​ Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121

* bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​

Sep 13 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,508 0.00
Pfizer Inc. (PFE.N) $35.76 -0.25
Merck & Co., Inc. (MRK.N) $54.55 -0.43
Sanofi SA (SASY.PA) €64.70 --
GlaxoSmithKline plc (GSK.L) 1,324.60 --
Eli Lilly and Co (LLY.N) $77.55 0.00

Earnings vs. Estimates